Early trials of allogeneic marrow transplantation for homozygous thalassemia were disappointing in patients older than 16, with four of six patients dying early of graft-versus-host disease-related complications, one patient dying at 9 months of infection due t o graft failure, and one dying at 6 years of recurrent thalassemia. Three classes of risk could be identified in analyses of results of transplantation in younger patients using the criteria of degree of hepatomegaly, the presence or absence of portal fibrosis, and a history of adequate or inadequate chelation therapy. Patients for whom all three criteria were adverse constituted a very high risk group (class 3) for marrow transplantation. On the basis of these analyses, a conditioning regimen was designed that yielded superior results for class 3 patients under 17 years of age. Most patients older than 16 years presenting for trans-REATMENT of homozygous thalassemia with a pro-T gram of intensive red blood cell transfusion and iron chelation can control the major complications of the genetic disorder. However, thalassemia remains a progressive condition that is frequently lethal in young adults who have not received adequate chelation. The most common reason for this inadequate chelation is poor patient discipline in following an intimidating and complex protocol, but irregular chelation is often a consequence of toxic or social factors. Iron overload as a consequence of hemolysis and transfusion is the principal cause of complications, but blood-borne viral inkctions also contribute to liver damage.
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Bone marrow transplantation (BMT) provides a hematologic cure of the underlying genetic Early attempts at BMT in thalassemia were reserved for patients aged less than 5 years,' and it was subsequently shown that the best results are obtained in young patients who have been regularly transfused and chelated with deferoxamine so that organ damage is minimal at the time of transplantat i~n .~
The early results of marrow transplantation in patients older than 16 years were very disappointing, with no disease-free survivors beyond 100 days (personal observations, see below). Attempts at treating older patients were therefore halted in July 1986.
In a group of 222 thalassemic patients aged 1 through 15 years, the probabilities of survival and of event-free sarvival were 82% and 75%, respectively, after BMT from HLAidentical donors3 It was also shown that, in this group of patients, the results of transplantation were related to the condition of the patient at the time of transplant and not to age. Three classes of risk were established based on the degree of hepatomegaly, the presence or absence of portal fibrosis, and a history of adequate or inadequate chelation treatment.3 When patients were categorized id this manner, it was clear that the transplantation regimen used for class 1 and 2 patients was not adequate for those in class 3, and a different regimen was devised for treating class 3 patients. Early results with the use of this regimen in younger patients are encouraging and will be published elsewhere.
Most older patients presenting for marrow transplantation have disease characteristics that place them in class 3. As a consequence of the improved results with the new class plantation have disease characteristics that place them in class 3 and, because of the improved results with the new class 3 regimen in younger patients, a study was designed t o treat patients older than 16 years using treatment regimens assigned on the basis of disease class. Twenty patients were treated using this protocol and, with a minimum follow-up of 9 months, there have been three early deaths, one patient has recurrent thalassemia, and 16 patients are alive diseasefree. The actuarial probabilities of survival, disease-free survival, and rejection are 0.85, 0.80, and 0.05, respectively, with a survival plateau extending from 6 months t o 3 years. Marrow transplantation is a reasonable option for adults with progressive thalassemia who have suitable donors.
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3 regimen, we broadened patient eligibility in October 1988 to include thalassemic patients of all ages, selecting the preparative regimen according to disease class.
This report describes the results of marrow transplantation in 26 adult thalassemic patients aged 17 through 26 years.
MATERIALS AND METHODS
Between February 23, 1984 and January 10, 1991, 26 patients more than 16 years of age were transplanted for the treatment of homozygous p-thalassemia.
Recipients and donors were genotypically HLA-identical and mixed leukocyte culture (MLC) nonreactive siblings. Eight patients had minor A B 0 incompatibility with their donors, all other donorhecipient pairs were A I 3 0 identical.
Six patients received transplants before July 1986 (group A), using four different preparative regimens. From October 13, 1988 through January 10, 1991, 20 consecutive patients over the age of 16 years received transplants (group B) using preparative regimens assigned on the basis of disease class. The regimens are summarized in Table 1 . Disease status was categorized according to established criteria3 in which three risk factors were identified. These risk factors were defined as hepatomegaly greater than 2 cm, portal fibrosis of any degree, and inadequate compliance with the chelation regimen. Adequate chelation compliance was defined as chelation with deferoxamine initiated within 18 months of the first transfusion and administered subcutaneously for 8 to 10 hours at least 5 days each week. Inadequate compliance was failure to maintain adequate compliance, and this categorization could not be corrected by subsequent intensive chelation. Class 1 patients had none of these risk factors, class 2 patients had one or two risk factors, and class 3 patients had all three risk factors. Among the group A patients, one was categorized as class 2, and five were class 3. One patient was prepared for transplantation with a regimen consisting of busulfan (BU) 4.0 mg/kg daily administered orally in three divided doses on each of 4 consecutive days (total dose, 16 mg/kg), followed by cyclophosphamide (CY) 50 mg/kg administered intravenously (IV) on each of 4 consecutive days4 (protocol 2). In the other five patients, the BU dose was reduced to 3.5 mg/kg daily for 4 days, and the CY dose remained the same.
Among the group B patients, five were categorized as class 2, and 15 as class 3. Patients in class 2 were prepared for transplantation with BU 3.5 mg/kg administered orally in three divided doses on each of 4 consecutive days followed by CY 50 mg/kg administered IV on each of 4 consecutive days (protocol 6). Patients in class 3 received the same doses of BU as those in class 2, followed by CY 60 mg/kg administered IV on each of 2 consecutive days and equine antilymphocyte globulin (Lymphoglobuline Meriew) 10 mg/kg from day -5 to day +5 in continuous infusion over 12 hours (protocol 12). Prophylaxis against acute graft-versus-host disease (AGVHD) for protocol 2 consisted of methotrexate (MTX) IV 15 mg/m2 on day 1; 10 mg/m2 on days 3,6, and 11; and weekly thereafter for 100 days. The patients on protocol 3 received the same MTX therapy, except that CY 7.5 mg/kg was substituted for the day 1 MTX. Patients on protocols 4 and 5 received daily cyclosporine (CSP) for 1 year beginning on day -9 (protocol 4) or day -2 (protocol 5). Protocol 5 patients also received CY 7.5 mg/kg IV on day 1 and MTX 10 mg/m2 on days 3, 6, and 11. Group B patients received CSP for 1 year from day -2, and group B patients in class 3 received additionally CY 7.5 mg/kg on day +1 and MTX 10 mg/m2 on days 3 and 6 after transplantation. All CSP treatment regimens commenced with 5 mg/kg IV until day 5, then 3 mg/kg until day 21, which was then changed to 12.5 mg/kg orally as soon as oral administration could be tolerated.
Marrow was infused 36 hours after the last dose of CY and the date of marrow infusion was designated day 0. All patients were treated in positive-pressure isolation rooms and received nonabsorbable oral antibiotics. Acyclovir 15 mg/kg administered IV in three divided doses and prednisolone 0.5 mg/kg IV were initiated on day -2 and administered daily through the transplant period. Amphotericin 0.3 mg/kg was initiated prophylactically on day +9 and administered daily until day +21 with reduced or suspended doses when levels of creatinine and blood urea nitrogen were elevated. AGVHD and chronic GVHD (CGVHD) were graded according to the Seattle riter ria.^.^ The first choice drug for treatment of AGVHD was prednisolone at escalating doses up to 10 mg/kg depending on the degree and duration of GVHD.
Cytogenetic analyses were performed on unstimulated marrow and phytohemagglutinin-stimulated peripheral blood when the donor and recipient were of opposite sex. Globin-chain synthesis of marrow and peripheral blood reticulocytes was examined by incorporation of 3H-leucine followed by column or high performance liquid chromatography. Analyses of karyotype and of the hemoglobin synthesis pattern were first performed on peripheral blood and on bone marrow aspirates on day 13 posttransplant and repeated at 2-week intervals until day 60 posttransplant to demonstrate engraftment. Rejection was defined as the development of complete marrow aplasia or the reestablishment of host a/p globin synthesis ratio.
Liver biopsy was performed on all patients before transplantation. Liver hemosiderosis, portal fibrosis, chronic aggressive hepatitis, and chronic persistent hepatitis were evaluated according to a grading system and recorded as absent, mild, moderate, or severe.' Survival distributions were estimated by the product-limit method of Kaplan and Meier.8 In estimating event-free survival, rejection with recurrence of thalassemia and deaths were identified as events. The reference date for recording events and calculating statistics was October 1,1991.
Informed consent was obtained from all patients and from the parents of minors after the procedures and risks involved in marrow transplantation were explained in detail. Particular emphasis was placed on discussing the option of continuing conventional management with transfusions and chelation. Tables 2 
RESULTS

Patient characteristics before transplantation are shown in
DISCUSSION
The six patients in group A were treated with a succession of regimens when preliminary studies were under way. The poor results in these older patients with advanced complications were discouraging and studies in such patients were interrupted until more experience was acquired in patients under the age of 17 years.
Analysis of the outcome of transplantation in patients under the age of 17 years showed that the mortality of thalassemic patients undergoing BMT from HLA-identical 626  17lM  636  21lF  643  17lM  675  23/F  679  21lF  683  191M  684  26lM  686  191M  687  21lM  688  191M  690  24lM  709  181M  712  17lM  716  181M  719  181M   205  274  450  480  428   188  250  260  300  600  570  162  252  310  456  314  230  230  263 Abbreviations as in Table 2 . *Serum ferritin levels (pgIL). tcentimeters below costal margin.
For donors correlates with the level of complications acquired during the conventional treatment of the disease. It was shown that hepatomegaly, the presence of portal fibrosis, and a history of inadequate iron chelation treatment with deferoxamine were negative prognostic indicators for the outcome of marrow transplantation. Among other pretransplant characteristics, age and the number of transfusions received before conditioning for transplantation did not significantly affect survival. We have used the three prognostic factors to categorize thalassemic patients before transplant into thtee classes. Class 1 presents with no factors, while class 3 has all three factors and class 2 has one or two of the three factors.
, The preparative regimens used for transplantation in classes 1 and 2 were poorly tolerated by patients in class 3. In dealing with a similar problem using BU and CY for the treatment of hematologic malignancy, Tutschka et a19 showed that toxicity could be reduced by reducing the dose of CY from 200 mg/kg over 4 days to 120 mg/kg over 2 days. In the treatment of malignancy, this regimen did not appear to be associated with an increase in graft rejection. Transplantation for the treatment of thalassemia is associated with a relatively high rejection rate and this discouraged the use of such a regimen for patients with class 1 or class 2 disease. However, the balance of risks for class 3 patients For personal use only. on October 30, 2017. by guest www.bloodjournal.org From suggested that such a regimen might reduce the risk of transplant-related mortality in circumstances in which rejection was not associated with early death. In an attempt to reduce the probability of rejection, antilymphocyte globulin was administered during the peritransplant period. In January 1988, a new treatment strategy was adopted for adult patients, in which class 1 and class 2 patients were treated with protocol 6 and class 3 patients were treated with protocol 12. Patients were accepted for transplantation without regard to age. Patients 17 years of age or older receiving transplants after this change of strategy constitute group B in the present report, and of these, 5 were of class 2 and 15 of class 3. Of 15 patients included in class 3 , 3 died and 1-rejected the graft and is alive with thalassemia, whereas all 5 patients of class 2 are currently alive without thalassemia. The results for group B patients are superior to those of the group A patients. Of the six group A patients, one each was treated with regimens 2 and 3, and two each were treated with regimens 4 and 5. The very small numbers treated with each regimen would not support any claims about the superiority of regimens 6 and 12. The two groups were separated in time. By the time the group B patients were treated, we had gained experience with younger patients that may have influenced us in many ways other than selecting treatment regimens. We do not know whether the improved results for group B patients were due to different regimens or to other factors and we are not aware of any change in the criteria used in selecting patients for transplantation.
All patients reported here had extramedullary organ damage associated with thalassemia and its treatment by transfusion and iron chelation. In most cases (class 3), these complications were severe and indicated a poor prognosis with continued conventional therapy. Transplantation cured the marrow defects in nearly all the patients and experience in the use of this treatment for aplastic anemialo or leukemia" suggests that the cure will be permanent. However, transplantation has not immediately reversed the nonmarrow complications, mainly liver damage, and prolonged follow-up will be necessary to determine the outcome for these patients. It is reasonable to expect that removal of the continuing cause for the organ damage will modify progression and permit healing of the damaged organs.
We propose that adults with thalassemia who have HLA-identical donors should be invited to discuss the probability of event-free survival after BMT.
